Ascelia Pharma publishes prospectus in connection with Initial Public Offering on Nasdaq Stockholm

by | Feb 21, 2019

Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) has decided to issue new shares to the general public in Sweden and Denmark as well as institutional investors in Sweden and abroad (the “Offering”).

The Company’s Board of Directors also intend to apply for admission to trading of the Company’s shares on Nasdaq Stockholm after Nasdaq Stockholm AB’s announcement that the Company complies with Nasdaq Stockholm’s listing requirements, provided that certain conditions and customary requirements, including the dispersion requirement for the Company’s shares, are fulfilled.

The prospectus for the Offering, including the price and other terms of the Offering, is published today. The first day of trading is expected to be March 13, 2019.


Press inquiries should be adressed to:

Peter Benson, Msc

Chairman & General Partner